PUBLIC CONTRACT · 2025
Ajuste direto para aquisição de R1090, E574, E391, I202 e I258.
- Contract value
- €4,644.23
- Signed on
- 19 March 2025
- Procedure
- Direct award, general (Ajuste Direto Regime Geral)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 11296397PUBLISHED SUBJECT
Ajuste direto para aquisição de R1090 - Ranibizumab [10 mg/ml; 0,23; intravitreo; f/amp] doentes em tratamento, E574 - Everolímus [2.5 mg; cáp/comp], E391- Everolímus [5 mg; cáp/comp], I202 - Imatinib [100mg; cáp/comp] e I258 - Imatinib [400 mg; cáp/comp].
WHO CONTRACTED
Parties involved
- Place of performance
- Portugal
- NUTS region
- PTZZZ - Extra-Regio NUTS 3 (Todos)
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- NOVARTIS FARMA-PROD.FARMACÊUTICOS,SA. · Tax ID 500063524
HOW MUCH AND WHEN
Values and timeline
- Contract price
- €4,644.23
- Procedure base price
- €69,059.94
- Total effective price
- Not reported on Portal BASE
- Publication date
- 20 March 2025
- Award date
- 19 March 2025
- Signing date
- 19 March 2025
- Performance period
- 306 days
The contract price is the value agreed in the contract, not the amount paid.
HOW IT WAS CONTRACTED
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Direct award, general (Ajuste Direto Regime Geral)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 24.º, n.º 1, alínea e), subalínea ii) do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- Not stated
- Centralised procedure
- Yes
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 7488653
KEEP EXPLORING
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.